Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors.
The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.
Inflectra carries biosimilar labeling designation, but is not interchangeable
Physicians hesitant to use biosimilars, but understand that payers may hold sway
2. Five Major EU Markets
Insights and strategic recommendations
Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
Payers use biosimilars to pressure originators on pricing
Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
Biosimilars will be used as price benchmarks for pipeline agents
Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
List of Tables:
Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country